25 completed, 3 unknown, 2 recruiting, 2 withdrawn. 34 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 34 | Completed 25, Unknown 3, Recruiting 2, Withdrawn 2, Enrolling by invitation 1, Terminated 1 |
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Dengue Fever: new trials by email Literature Review of Dengue Fever trials Research Report on Dengue Fever
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2) Resomelagon, Placebo, Standard Treatment - Dengue Fever | Phase 2 | Recruiting | Federal University of Minas Gerais | 120 | 2026-03-20 | 2026-09-15 |
| To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-associated Thrombocytopenia Carica Papaya Leaf Extract Group, standard treatment - Dengue Fever, Papaya Leaf Extract | Phase 2 | Enrolling by invitation | Ziauddin Hospital | 100 | 2025-10-01 | 2025-09-15 |
| A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan TDV, Placebo - Dengue Fever | Phase 2 / Phase 3 | Completed | Takeda | 187 | 2025-01-31 | 2025-12-30 |
| Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients CPLE, Placebo - Dengue Fever | Phase 1 / Phase 2 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 184 | 2024-06-01 | 2025-04-25 |
| Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE) Zanamivir, Placebo - Dengue Fever | Phase 2 | Recruiting | George Washington University | 74 | 2024-03-15 | 2026-07-29 |
| Role of Vitamin D in Prevention of Dengue Haemorrhagic Fever and Dengue Shock Syndrome Arm-2 : 2,00,000 IU Vitamin D3 oral solution , Arm-3: 4,00,000 IU Vitamin D3 oral solution - Dengue Fever | Phase 2 | Unknown | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 120 | 2023-06-01 | 2023-10-06 |
| Study of AT-752 in Patients With Dengue Infection AT-752, Placebo - Dengue Fever | Phase 2 | Terminated | Atea Pharmaceuticals, Inc. | 21 | 2022-04-29 | 2024-03-05 |
| Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults CYD Dengue Vaccine, Placebo (NaCl 0.9%) vaccine group - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 133 | 2019-11-06 | 2024-07-19 |
| IC14 in Adult Patients With Dengue Fever IC14, Placebo - Dengue Fever | Phase 2 | Withdrawn | Implicit Bioscience | 2019-05-01 | 2026-05-05 | |
| Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults TDV - Dengue Fever | Phase 2 | Completed | Takeda | 30 | 2018-12-28 | 2025-09-08 |
| Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Celgosivir, Modipafant 50mg, Placebo - Dengue Fever | Phase 1 / Phase 2 | Withdrawn | Singapore General Hospital | 2018-12-01 | 2020-03-23 | |
| Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule CYD Dengue Vaccine (5 dose formulation), Placebo, NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 118 | 2016-07-01 | 2022-03-24 |
| Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age CYD Dengue Vaccine, Placebo (Sodium chloride 0.9%) - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1050 | 2016-05-02 | 2022-03-24 |
| Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule CYD Dengue Vaccine (5-dose formulation), Placebo, NaCl 0.9% - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 251 | 2016-04-14 | 2022-03-24 |
| Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore Takeda's Tetravalent Dengue Vaccine Candidate (TDV), Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV) - Dengue Fever | Phase 2 | Completed | Takeda | 351 | 2015-06-03 | 2019-08-28 |
| Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants Takeda's Tetravalent Dengue Vaccine Candidate (TDV), TDV Placebo - Dengue Fever | Phase 2 | Completed | Takeda | 1800 | 2014-12-05 | 2020-02-24 |
| Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) TDV Liquid Formulation 1, TDV Liquid Formulation 2, TDV IDT Lyophilized - Dengue Fever | Phase 2 | Completed | Takeda | 1002 | 2014-08-06 | 2019-07-18 |
| Efficacy and Safety of Ivermectin Against Dengue Infection 2 days Ivermectin, 3 days Ivermectin, Placebo - Dengue Fever | Phase 2 / Phase 3 | Unknown | Mahidol University | 360 | 2014-02-01 | 2015-11-02 |
| Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine CYD Dengue Vaccine, Japanese Encephalitis Vaccine - Dengue, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 90 | 2013-11-05 | 2022-03-24 |
| Celgosivir as a Treatment Against Dengue celgosivir, placebo - Dengue Fever | Phase 1 / Phase 2 | Completed | Singapore General Hospital | 50 | 2012-07-01 | 2013-12-02 |
Showing 20 of 34. Sign in to see all of them.
Dengue (34) · Severe Dengue (17) · Hemorrhagic Fevers, Viral (2) · Virus Diseases (2) · Acquired Immunodeficiency Syndrome (1) · Infections (1) · Vector Borne Diseases (1) · Yellow Fever (1)
Arbovirus Infections (34) · Flaviviridae Infections (34) · Flavivirus Infections (34) · Mosquito-Borne Diseases (34) · RNA Virus Infections (34) · Infections (33) · Vector Borne Diseases (33) · Hemorrhagic Fevers, Viral (32) · Virus Diseases (32) · Blood-Borne Infections (1) · Communicable Diseases (1) · Genital Diseases (1) · HIV Infections (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1)
Sodium Chloride (4) · ChimeriVax (2) · Dengue Vaccines (2) · Dosage Forms (2) · celgosivir (2) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · AT-752 (1) · Cholecalciferol (1) · Hepatitis A Vaccines (1) · Ivermectin (1) · JPT1 protein, human (1) · Japanese Encephalitis Vaccines (1) · Measles-Mumps-Rubella Vaccine (1) · Pneumococcal Vaccines (1) · Ribavirin (1)
Sanofi Pasteur, a Sanofi Company (13) · Takeda (5) · Sanofi (3) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (2) · Singapore General Hospital (2) · U.S. Army Medical Research and Development Command (2) · Atea Pharmaceuticals, Inc. (1) · Federal University of Minas Gerais (1) · George Washington University (1) · Guangzhou 8th People's Hospital (1) · Implicit Bioscience (1) · Mahidol University (1) · Ziauddin Hospital (1)
Colombia (5) · Singapore (5) · United States (5) · Brazil (4) · Philippines (4) · Thailand (4) · Mexico (3) · Puerto Rico (3) · Bangladesh (2) · Honduras (2) · India (2) · Peru (2) · Vietnam (2) · Australia (1) · China (1)
Aileen Chang, MD (1) · Alberto Santiago-Cornier, MD (1) · Anna Quintero, MD (1) · Clemente Diaz-Perez, MD (1) · Domingo Chardon-Feliciano, MD (1) · Evelyn Matta-Fontanet, MD (1) · Ines O. Esquilin-Rivera, MD (1) · Jan Agosti, MD (1) · Javier Morales-Ramirez, MD (1) · Jenny Low, Dr (1) · Jorge Bertran-Pasarell, MD (1)
PMID 40099800, PMID 18337339, PMID 21976579, PMID 22863660, PMID 22894958, PMID 22975340, PMID 23540847, PMID 23839107, PMID 24021313, PMID 24067553, PMID 24877997, PMID 25483647, PMID 26175027, PMID 26214039, PMID 26291554, PMID 26794905, PMID 27102820, PMID 27509020, PMID 28137799, PMID 28365225, PMID 29122463, PMID 29897841, PMID 30241510, PMID 30986790, PMID 31464558, PMID 31843269, PMID 32119591, PMID 32197107, PMID 32572472, PMID 32932330, PMID 33113295, PMID 33124646, PMID 33212067, PMID 33332778, PMID 33534885, PMID 33626291, PMID 33684559, PMID 33711074, PMID 33822015, PMID 34107180, PMID 34641339, PMID 34742052, PMID 34937145, PMID 35078666, PMID 35172054, PMID 35364022, PMID 36566761, PMID 36764470, PMID 36803992, PMID 37470445
2014 (4), 2018 (1)